TY - JOUR
T1 - Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease–Associated Hepatocellular Carcinoma in the United States
AU - Karim, Mohammad A.
AU - Singal, Amit G.
AU - Kum, Hye Chung
AU - Lee, Yi Te
AU - Park, Sulki
AU - Rich, Nicole E.
AU - Noureddin, Mazen
AU - Yang, Ju Dong
N1 - Funding Information:
Funding Dr Karim’s research is funded in part by a fellowship supported by the Cancer Prevention and Research Institute of Texas (CPRIT), United States grant award RP170259 (to Mohammad A. Karim, PhD; PI: Shine Chang, PhD and Sanjay Shete, PhD). Dr Singal’s research is funded by National Institute of Health R01 MD012565 , U01 CA230694 , and R01 CA256977 . Dr Karim and Dr Kum’s research is funded in part by the Population Informatics Lab , and the Texas Virtual Data Library (ViDaL) at Texas A&M University. Dr Yang’s research is supported by American College of Gastroenterology Junior Faculty Development Award, Department of Defense Peer Reviewed Cancer Research Program, United States Career Development Award (CA191051). The American College of Gastroenterology, United States, the CPRIT, Department of Defense, United States, National Institutes of Health, the Population Informatics Lab, and the ViDaL at Texas A&M University had no role in the collection of data; the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
Funding Dr Karim's research is funded in part by a fellowship supported by the Cancer Prevention and Research Institute of Texas (CPRIT), United States grant award RP170259 (to Mohammad A. Karim, PhD; PI: Shine Chang, PhD and Sanjay Shete, PhD). Dr Singal's research is funded by National Institute of Health R01 MD012565, U01 CA230694, and R01 CA256977. Dr Karim and Dr Kum's research is funded in part by the Population Informatics Lab, and the Texas Virtual Data Library (ViDaL) at Texas A&M University. Dr Yang's research is supported by American College of Gastroenterology Junior Faculty Development Award, Department of Defense Peer Reviewed Cancer Research Program, United States Career Development Award (CA191051). The American College of Gastroenterology, United States, the CPRIT, Department of Defense, United States, National Institutes of Health, the Population Informatics Lab, and the ViDaL at Texas A&M University had no role in the collection of data; the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Publisher Copyright:
© 2023 AGA Institute
PY - 2023/3
Y1 - 2023/3
N2 - Background & Aims: The extent to which nonalcoholic fatty liver disease (NAFLD) contributes to hepatocellular carcinoma (HCC) prevalence in contemporary practices and whether there are any etiologic differences in surveillance receipt, tumor stage, and overall survival (OS) remain unclear. We aimed to estimate the burden of NAFLD-related HCC and magnitude of associations with surveillance receipt, clinical presentation, and outcomes in a contemporary HCC cohort. Methods: In a cohort of HCC patients from the Surveillance, Epidemiology and End Results–Medicare database between 2011 and 2015, we used multivariable logistic regression to identify factors associated with surveillance receipt, early-stage tumor detection, and curative treatment. Cox regression was used to identify factors associated with OS. Results: Among 5098 HCC patients, NAFLD was the leading etiology, accounting for 1813 cases (35.6%). Compared with those with hepatitis C–related HCC, NAFLD was associated with lower HCC surveillance receipt (adjusted odds ratio, 0.22; 95% confidence interval [CI], 0.17–0.28), lower early-stage HCC detection (adjusted odds ratio, 0.49; 95% CI, 0.40–0.60), and modestly worse OS (adjusted hazard ratio, 1.20; 95% CI, 1.09–1.32). NAFLD subgroup analysis showed that early-stage HCC, absence of ascites/hepatic encephalopathy, surveillance, and curative treatment receipt were associated with improved OS. NAFLD patients with coexisting liver disease were more likely to have surveillance, early-stage detection, curative treatment, and improved OS than NAFLD patients without coexisting liver diseases. Conclusions: NAFLD is the leading etiology of HCC among Medicare beneficiaries. Compared with other etiologies, NAFLD was associated with lower HCC surveillance receipt, early-stage detection, and modestly poorer survival. Multifaceted interventions for improving surveillance uptake are needed to improve prognosis of patients with NAFLD-related HCC.
AB - Background & Aims: The extent to which nonalcoholic fatty liver disease (NAFLD) contributes to hepatocellular carcinoma (HCC) prevalence in contemporary practices and whether there are any etiologic differences in surveillance receipt, tumor stage, and overall survival (OS) remain unclear. We aimed to estimate the burden of NAFLD-related HCC and magnitude of associations with surveillance receipt, clinical presentation, and outcomes in a contemporary HCC cohort. Methods: In a cohort of HCC patients from the Surveillance, Epidemiology and End Results–Medicare database between 2011 and 2015, we used multivariable logistic regression to identify factors associated with surveillance receipt, early-stage tumor detection, and curative treatment. Cox regression was used to identify factors associated with OS. Results: Among 5098 HCC patients, NAFLD was the leading etiology, accounting for 1813 cases (35.6%). Compared with those with hepatitis C–related HCC, NAFLD was associated with lower HCC surveillance receipt (adjusted odds ratio, 0.22; 95% confidence interval [CI], 0.17–0.28), lower early-stage HCC detection (adjusted odds ratio, 0.49; 95% CI, 0.40–0.60), and modestly worse OS (adjusted hazard ratio, 1.20; 95% CI, 1.09–1.32). NAFLD subgroup analysis showed that early-stage HCC, absence of ascites/hepatic encephalopathy, surveillance, and curative treatment receipt were associated with improved OS. NAFLD patients with coexisting liver disease were more likely to have surveillance, early-stage detection, curative treatment, and improved OS than NAFLD patients without coexisting liver diseases. Conclusions: NAFLD is the leading etiology of HCC among Medicare beneficiaries. Compared with other etiologies, NAFLD was associated with lower HCC surveillance receipt, early-stage detection, and modestly poorer survival. Multifaceted interventions for improving surveillance uptake are needed to improve prognosis of patients with NAFLD-related HCC.
KW - Liver Cancer
KW - NAFLD
KW - NASH
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=85129012492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129012492&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2022.03.010
DO - 10.1016/j.cgh.2022.03.010
M3 - Article
C2 - 35307595
AN - SCOPUS:85129012492
SN - 1542-3565
VL - 21
SP - 670-680.e18
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 3
ER -